Efficacy and tolerability of osimertinib with dabrafenib and trametinib in BRAF V600E acquired EGFR -mutant non-small cell lung cancer: a case series.

V600E mutation post progression on osimertinib. This study supports molecular profiling at osimertinib progression and provides additional information on the appropriate sequencing of targeted therapies in the EGFR tyrosine kinase inhibitor resistance setting.